Stifel Nicolaus Increases Enfusion (NYSE:ENFN) Price Target to $13.00

Enfusion (NYSE:ENFN) had its target price raised by research analysts at Stifel Nicolaus from $11.00 to $13.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 24.16% from the stock’s current price.

Enfusion Trading Down 2.6 %

NYSE:ENFN opened at $10.47 on Wednesday. The firm’s fifty day simple moving average is $9.67 and its 200 day simple moving average is $8.99. Enfusion has a twelve month low of $7.52 and a twelve month high of $11.38. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of 261.82, a PEG ratio of 3.98 and a beta of 0.97.

Insider Transactions at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 36.44% of the company’s stock.

Hedge Funds Weigh In On Enfusion

A number of institutional investors and hedge funds have recently bought and sold shares of ENFN. TenCore Partners LP purchased a new stake in shares of Enfusion during the third quarter valued at approximately $3,938,000. Dimensional Fund Advisors LP grew its holdings in Enfusion by 57.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after purchasing an additional 191,436 shares in the last quarter. Impax Asset Management Group plc increased its stake in Enfusion by 25.4% during the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after buying an additional 136,948 shares during the period. Scalar Gauge Management LLC lifted its holdings in Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after buying an additional 110,000 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Enfusion in the 3rd quarter valued at about $892,000. Hedge funds and other institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.